242 related articles for article (PubMed ID: 26441837)
1. Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.
Inagaki T
Front Endocrinol (Lausanne); 2015; 6():147. PubMed ID: 26441837
[TBL] [Abstract][Full Text] [Related]
2. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
Su X; Kong Y; Peng D
Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress.
Schaap FG; Kremer AE; Lamers WH; Jansen PL; Gaemers IC
Biochimie; 2013 Apr; 95(4):692-9. PubMed ID: 23123503
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
Woo YC; Xu A; Wang Y; Lam KS
Clin Endocrinol (Oxf); 2013 Apr; 78(4):489-96. PubMed ID: 23134073
[TBL] [Abstract][Full Text] [Related]
7. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China.
Li H; Dong K; Fang Q; Hou X; Zhou M; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2013 Mar; 58(3):557-63. PubMed ID: 23142063
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21.
Gong Q; Zhang X; Sun Y; Shen J; Li X; Xue C; Liu Z
J Mol Med (Berl); 2022 Nov; 100(11):1587-1597. PubMed ID: 36102936
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development.
Liu J; Dalamaga M
Metabol Open; 2021 Dec; 12():100153. PubMed ID: 34917917
[TBL] [Abstract][Full Text] [Related]
10. The role of FGF21 and its analogs on liver associated diseases.
Falamarzi K; Malekpour M; Tafti MF; Azarpira N; Behboodi M; Zarei M
Front Med (Lausanne); 2022; 9():967375. PubMed ID: 36457562
[TBL] [Abstract][Full Text] [Related]
11. FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD.
Wang Z; Sun T; Yu J; Li S; Gong L; Zhang Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):351. PubMed ID: 38179757
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
[TBL] [Abstract][Full Text] [Related]
13. Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.
Zhang F; Yu L; Lin X; Cheng P; He L; Li X; Lu X; Tan Y; Yang H; Cai L; Zhang C
Mol Endocrinol; 2015 Oct; 29(10):1400-13. PubMed ID: 26308386
[TBL] [Abstract][Full Text] [Related]
14. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target.
Liu WY; Huang S; Shi KQ; Zhao CC; Chen LL; Braddock M; Chen YP; Feng WK; Zheng MH
Expert Opin Ther Targets; 2014 Nov; 18(11):1305-13. PubMed ID: 25077735
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
16. Metabolic actions of fibroblast growth factor 21.
Cuevas-Ramos D; Aguilar-Salinas CA; Gómez-Pérez FJ
Curr Opin Pediatr; 2012 Aug; 24(4):523-9. PubMed ID: 22732636
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
[TBL] [Abstract][Full Text] [Related]
18. The potential function and clinical application of FGF21 in metabolic diseases.
Chen Z; Yang L; Liu Y; Huang P; Song H; Zheng P
Front Pharmacol; 2022; 13():1089214. PubMed ID: 36618930
[TBL] [Abstract][Full Text] [Related]
19. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.
Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH
Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
